Abstract
Recurrence of Crohns disease (CD) is extremely frequent after surgery and its prevention remains a fundamental problem in the medical management of these patients. As of today, none of the medications traditionally used to treat the spontaneous disease (i.e. mesalamine, steroids, immunosuppressives and antibiotics) has shown a clear benefit. Recent data, coming from our center and from a small RCT do indicate that infliximab is extremely effective in preventing this complication in the large majority of patients. While additional, larger studies may be desirable, the strength and consistency of the available data suggest that future trials may merely confirm these observations. A number of issues however remain to be solved and include the long term strategy in patients treated for years with infliximab, whether treating early endoscopic lesions may be as effective as preventing them and whether immuno-soppressives should be used together with infliximab. A thorough understanding of the mechanisms by which infliximab appears so effective in the postoperative setting may provide us with essential information regarding patients ’ management and, ultimately, highlight the molecular mechanisms at the very basis of Crohns disease.
Current Drug Targets
Title: Anti-TNFs for Postoperative Recurrence in Crohns Disease: The Ifs and Hows
Volume: 11 Issue: 2
Author(s): D. Sorrentino, A. Paviotti and G. Fiorino
Affiliation:
Abstract: Recurrence of Crohns disease (CD) is extremely frequent after surgery and its prevention remains a fundamental problem in the medical management of these patients. As of today, none of the medications traditionally used to treat the spontaneous disease (i.e. mesalamine, steroids, immunosuppressives and antibiotics) has shown a clear benefit. Recent data, coming from our center and from a small RCT do indicate that infliximab is extremely effective in preventing this complication in the large majority of patients. While additional, larger studies may be desirable, the strength and consistency of the available data suggest that future trials may merely confirm these observations. A number of issues however remain to be solved and include the long term strategy in patients treated for years with infliximab, whether treating early endoscopic lesions may be as effective as preventing them and whether immuno-soppressives should be used together with infliximab. A thorough understanding of the mechanisms by which infliximab appears so effective in the postoperative setting may provide us with essential information regarding patients ’ management and, ultimately, highlight the molecular mechanisms at the very basis of Crohns disease.
Export Options
About this article
Cite this article as:
Sorrentino D., Paviotti A. and Fiorino G., Anti-TNFs for Postoperative Recurrence in Crohns Disease: The Ifs and Hows, Current Drug Targets 2010; 11 (2) . https://dx.doi.org/10.2174/138945010790309920
DOI https://dx.doi.org/10.2174/138945010790309920 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis, Docking and Anti-Tumor Activity of β-L-1,3-Thiazolidine Pyrimidine Nucleoside Analogues
Medicinal Chemistry Unique Biology of Mcl-1: Therapeutic Opportunities in Cancer
Current Molecular Medicine In vitro Generated Mesenchymal Stem Cells: Suitable Tools to Target Insulin Dependent Diabetes Mellitus?
Current Stem Cell Research & Therapy Advances in Biologic Agents for the Treatment of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Management Of Elderly Patients With Diffuse Large B-Cell Lymphomas
Anti-Cancer Agents in Medicinal Chemistry Schizophrenia: A Systematic Review of the Disease State, Current Therapeutics and their Molecular Mechanisms of Action
Current Medicinal Chemistry Breast Reconstruction – A Historical Perspective on Available Techniques for Patients Electing Bilateral Mastectomy
Current Cancer Therapy Reviews Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Current Drug Targets Antifungal Agents in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design New Treatment Strategies for Multiple Myeloma by Targeting BCL-2 and the Mevalonate Pathway
Current Pharmaceutical Design Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry Receptor Tyrosine Kinases as Target for Anti-Cancer Therapy
Current Pharmaceutical Design Predictive Factors of Febrile Neutropenia Induced by Anticancer Chemotherapy in the South of Tunisia
Reviews on Recent Clinical Trials NGR-based Strategies for Targeting Delivery of Chemotherapeutics to Tumor Vasculature
Anti-Cancer Agents in Medicinal Chemistry The Evolving AML Genomic Landscape: Therapeutic Implications
Current Cancer Drug Targets Biological Basis of Novel Therapies for Myelodysplastic Syndrome
Current Cancer Therapy Reviews BIBR 1532 Increases Arsenic Trioxide-mediated Apoptosis in Acute Promyelocytic Leukemia Cells: Therapeutic Potential for APL
Anti-Cancer Agents in Medicinal Chemistry Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia
Current Gene Therapy Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
Current Cancer Drug Targets